Announcements
Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of ELU-001,…
Read More
Excerpt from the Press Release: LAWRENCEVILLE, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 55 as treated patients randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given as a prophylactic or a treatment for SARS-CoV-2 infection, protects against SARS-CoV-2-induced diffuse alveolar damage (DAD), which is associated with the early stages of acute respiratory distress syndrome (ARDS). Additional in vitro data show that SLV213 greatly enhances the…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, has unveiled preclinical data supporting drug discovery efforts involving its Precision Medicine Platform at the European Society of Cardiology Heart Failure 2021 (ESC-HF) meeting. The…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies at the virtual Society of Cardiovascular Computed Tomography (SCCT) 16th Annual Scientific Meeting.…
Read More
On May 25th, 2021 TrialStat’s very own Christopher Kata, and Heather Williams hosted an incredible webinar with our guest Speaker John Amrhein, VP of McDougall Scientific. John presented his perspective on “Accelerating Trials Through Innovative Clinical Trial Designs” and taking questions from our live audience! Download the Slide Deck, and Watch The Webinar Recording On…
Read More Meet with Christopher Kata, Director of Sales & Marketing on June 27 – July 1st! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 27th – July 1st 2021Where: It’s Virtual!Registration: https://www.diaglobal.org/en/cart Recognizing and adapting to a new era of global change and uncertainty, DIA’s key tenets remain unchanged. Patients are our story, we…
Read More
On April 21st, we hosted our virtual networking meeting focused on the critical benefits of engaging a Statistician early in your clinical development program. Heather and Christopher along with their guest John Amrhein of McDougall Scientific facilitated a wonderful presentation and discussion around the many different and crucial benefits of engaging a Statistician early to…
Read More
On March 23rd, we hosted our virtual networking meeting focused on the complexities of imaging based clinical trials. Heather and Christopher along with their guest Malachi Bierstein of ScienceMedia facilitated a wonderful presentation and discussion around the benefits of effective site training and it’s impact on clinical trial performance! Thank you to everyone who participated…
Read More
On February 25th, we hosted our virtual networking meeting focused on the complexities of imaging based clinical trials. Thank you to everyone who participated in this exciting discussion. For those of you who wanted to join but could not, you can watch the recording below, and also register for our upcoming meetings! Register for the…
Read More